The Current Landscape of Metastatic Breast Cancer: A Pathology Guide on Emerging Biomarkers.

Background/Objectives: Metastatic breast cancer (MBC) remains a daunting clinical challenge, accounting for approximately 90% of all breast cancer-related deaths. The management of MBC has shifted from traditional chemotherapy to a sophisticated, biomarker-driven model of precision oncology. This evolution is predicated on the ability of biomarkers to provide prognostic and predictive information. The objective of this review is to provide a comprehensive synthesis of the current landscape of biomarker testing in MBC, detailing which biomarkers to test and the clinical rationale for doing so. Methods: This is a comprehensive review based on current international clinical practice guidelines, peer-reviewed literature, and evidence regarding clinically actionable and emerging biomarkers in metastatic breast cancer. Results: Key biomarkers currently in routine use include the established estrogen receptor (ER), progesterone receptor (PR), and HER2, alongside newer, clinically actionable alterations such as mutations in PIK3CA and ESR1, germline/somatic BRCA1/2, and PD-L1 expression. Furthermore, liquid biopsy, particularly the analysis of circulating tumor DNA (ctDNA), is rapidly gaining prominence as a non-invasive tool for real-time disease monitoring and resistance detection, highlighting the critical need for re-testing at metastasis due to tumor heterogeneity. Conclusions: The future of personalized oncology in MBC will be defined by the seamless integration of dynamic biomarkers and cutting-edge technologies. The integration of AI and spatial transcriptomics will move the field of pathology beyond a static diagnosis to a more dynamic and predictive model, reinforcing the pathologist's role as the "molecular gatekeeper" for adaptive and personalized cancer care.